A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia.

Authors:
Dolstra H; Fredrix H; Maas F; Coulie PG; Brasseur F and 5 more

Journal:
J Exp Med

Publication Year: 1999

PMCID:
PMC2192993

PMID:
9892612

View on PubMed View on PMC
Journal Information

Full Title: J Exp Med

Abbreviation: J Exp Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Addendum: Resolvins suppress tumor growth and enhance cancer therapy.
Sulciner ML; Serhan CN; Gilligan MM and 18 more (2024) - Transparency Score: 2/6
Anti-PD-1 therapy triggers Tfh cell-dependent IL-4 release to boost CD8 T cell responses in tumor-d…
Ruggiu M; Guérin MV; Corre B and 9 more (2024) - Transparency Score: 3/6
Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children.
Bastard P; Gervais A; Taniguchi M and 87 more (2024) - Transparency Score: 3/6
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy.
Wang L; Xiao Y; Luo Y and 19 more (2024) - Transparency Score: 5/6
The effector program of human CD8 T cells supports tissue remodeling.
Delacher M; Schmidleithner L; Simon M and 32 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"these sequence data are available from embl/genbank/ddbj under accession number af103884 ."

Code Sharing
COI Disclosure
Evidence found in paper:

"This work was supported by grants from the Dutch Cancer Society (KUN 97-1508), the Ank van Vlissingen Foundation, and the Maurits and Anna de Kock Foundation."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025